8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2026

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (212) 605-0300

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Appointment of Director

On March 6, 2026, the Board of Directors (the “Board”) of LB Pharmaceuticals Inc (the “Company”) appointed Robert A. Lenz, to the Board, effectively immediately. Dr. Lenz will serve as a Class I director with a term expiring at the 2026 annual meeting of stockholders and until his successor has been elected and qualified. The Board also appointed Dr. Lenz to serve as a member of the Nominating and Corporate Governance Committee.

Pursuant to the Company’s non-employee director compensation policy, as a non-employee director, Dr. Lenz will receive (i) a $40,000 annual retainer for his service on the Board, as well as an additional annual retainer of $5,000 for service as a member of the Nominating and Corporate Governance Committee, (ii) an automatic initial grant of a stock option to purchase 20,000 shares of common stock under the Company’s 2025 Equity Incentive Plan (the “2025 Plan”), which vests in equal annual installments over a three-year period from the date of grant, and (iii) on the date of each annual stockholder meeting, an automatic grant of a stock option to purchase 10,000 shares of Common Stock under the 2025 Plan, which vests on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder’s meeting.

In addition, Dr. Lenz will enter into the Company’s standard indemnification and advancement agreement for directors and executive officers, the form of which was filed as Exhibit 10.12 to the Company’s Registration Statement on Form S-1, filed with the Securities and Exchange Commission on August 22, 2025. There is no arrangement or understanding between Dr. Lenz and any other person pursuant to which he was selected as a director, and there is no family relationship between Dr. Lenz and any of the Company’s other directors or executive officers. The Company is not aware of any transaction involving Dr. Lenz requiring disclosure under Item 404(a) of Regulation S-K.

Appointment of Chief Operating Officer

On March 4, 2026, the Board approved the promotion of Gad Soffer, the Company’s Chief Business Officer, to the position of Chief Operating and Business Officer, to serve in such position until his successor is appointed or until his earlier resignation or removal, effective immediately. Mr. Soffer’s biographical information is incorporated herein by reference as set forth in the Company’s final prospectus filed with the Securities and Exchange Commission (the “SEC”) on September 12, 2025.

Mr. Soffer’s employment is at-will. There are no arrangements or understandings between Mr. Soffer and any other persons pursuant to which Mr. Soffer was promoted as Chief Operating and Business Officer of the Company. There are also no family relationships between Mr. Soffer and any director or executive officer of the Company and he has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with his promotion to Chief Operating and Business Officer, Mr. Soffer’s annual base salary was increased to $505,000 and he will be eligible for an annual bonus with a target amount equal to 40% of his annual base salary.

A copy of the Company’s press release, dated March 9, 2026, announcing the appointment of Dr. Lenz to the Board is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1

Exhibit 99.1

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D.,

Ph.D. to Board of Directors

Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development

NEW YORK, March 9, 2026 (GLOBE NEWSWIRE) – LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors.

“We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals.

“I am pleased to join LB Pharma’s Board of Directors at this very exciting time for the Company, and contribute to its accelerating growth,” commented Robert Lenz, M.D., Ph.D. “I look forward to working with my fellow directors and this incredible management team to progress LB-102, an investigational therapy with the potential to become, if approved, a mainstay of psychiatric practice for the treatment of psychosis and mood disorders by offering patients a differentiated therapy with a balanced clinical benefit and tolerability profile.”

Dr. Robert Lenz is a veteran research and development leader, currently advising several biopharmaceuticals companies. Most recently, he served as the Executive Vice President and Head of Research and Development at Neumora Therapeutics, and prior to that, he spent over a decade at Amgen Inc. in key leadership roles, including Senior Vice President, Head of Global Development. Earlier in his career, Dr. Lenz held positions of increasing responsibility at Abbott Laboratories, ultimately serving as Divisional Vice President for Neuroscience, Anesthesia, and Psychiatry Development. Throughout his career, Dr. Lenz has overseen the development of multiple medicines through regulatory approval. He also serves on the board and scientific boards of several companies. Dr. Lenz earned his M.D. and Ph.D. with honors from the University of Maryland School of Medicine and completed his neurology residency at the University of California - Los Angeles. He holds a bachelor’s degree from Dickinson College and has been recognized with multiple awards for innovation and leadership in the pharmaceutical industry.

About LB Pharmaceuticals

LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive MDD, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a wide range of neuropsychiatric diseases.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102 and continuing advancement of LB-102 and the Company’s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media and Investor Contact:

Ellen Rose

erose@lbpharma.us